Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9749632 | 0.79 | MTNR1A (0.50) | — | |
| SCHEMBL9749184 | 0.79 | CYP1A2 (0.57) | ALDH1A1NPC1TDP1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL9750244 | 0.77 | TDP1 (0.52) | ALDH1A1TDP1KMT2AKDM4E | |
| SCHEMBL21914028 | 0.77 | ALDH1A1 (0.59) | ALDH1A1NPC1TDP1KMT2AHPGD | |
| SCHEMBL27926016 | 0.76 | CYP1A2 (0.60) | ALDH1A1TDP1KMT2AKDM4EMEN1 | |
| SCHEMBL11958401 | 0.75 | KMT2A (0.59) | ALDH1A1NPC1TDP1KMT2AKDM4E | |
| SCHEMBL7834822 | 0.75 | HDAC1 (0.57) | — | |
| SCHEMBL9614852 | 0.73 | CYP4F2 (0.63) | NPC1TDP1KDM4E | |
| SCHEMBL5173574 | 0.73 | ALDH1A1 (0.97) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL9692986 | 0.73 | PTPN22 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |